Sfoglia per Autore
The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC)
2020-01-01 Foerster, B.; Abufaraj, M.; Mari, A.; Seisen, T.; Bandini, M.; Schweitzer, D.; Czech, A. K.; Moschini, M.; D'Andrea, D.; Bianchi, M.; Hendricksen, K.; Roupret, M.; Briganti, A.; van Rhijn, B. W. G.; Chlosta, P.; Colin, P.; John, H.; Shariat, S. F.
Re: Siamak Daneshmand, Azadeh Nazemi. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. Eur Urol Focus 2020;6:639–41
2020-01-01 Basile, G.; Bandini, M.; Pederzoli, F.; Gallina, A.; Necchi, A.
Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer?
2020-01-01 Necchi, A.; Marandino, L.; Raggi, D.; Bandini, M.; Gallina, A.; Moschini, M.; Briganti, A.; Montorsi, F.
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study
2020-01-01 Bandini, M.; Pederzoli, F.; Madison, R.; Briganti, A.; Ross, J. S.; Niegisch, G.; Yu, E. Y.; Bamias, A.; Agarwal, N.; Sridhar, S. S.; Rosenberg, J. E.; Bellmunt, J.; Pal, S. K.; Galsky, M. D.; Luciano, R.; Gallina, A.; Salonia, A.; Montorsi, F.; Ali, S. M.; Chung, J. H.; Necchi, A.
A risk calculator predicting recurrence in lymph node metastatic penile cancer
2020-01-01 Bandini, M.; Spiess, P. E.; Pederzoli, F.; Marandino, L.; Brouwer, O. R.; Albersen, M.; Roussel, E.; de Vries, H. M.; Chipollini, J.; Zhu, Y.; Ye, D. -W.; Ornellas, A. A.; Catanzaro, M.; Hakenberg, O. W.; Heidenreich, A.; Haidl, F.; Watkin, N.; Ager, M.; Ahmed, M. E.; Karnes, J. R.; Briganti, A.; Salvioni, R.; Montorsi, F.; Azizi, M.; Necchi, A.
Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma
2020-01-01 Bandini, Marco; Ross, Jeffrey S; Zhu, Yao; Ye, Ding-Wei; Ornellas, Antonio A; Watkin, Nick; Ayres, Benjamin A; Hakenberg, Oliver W; Heidenreich, Axel; Salvioni, Roberto; Catanzaro, Mario; Raggi, Daniele; Giannatempo, Patrizia; Marandino, Laura; Haidl, Friederike; Pederzoli, Filippo; Briganti, Alberto; Montorsi, Francesco; Chipollini, Juan; Azizi, Mounsif; De Meerleer, Gert; Brouwer, Oscar R; Grass, G Daniel; Johnstone, Peter A; Albersen, Maarten; Spiess, Philippe E; Necchi, Andrea
Reply to Yunjin Bai, Yubo Yang, Yin Tang's Letter to the Editor, re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01, Study. Eur Urol 2020;77:636–43
2020-01-01 Bandini, M.; Necchi, A.
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆
2020-01-01 Bandini, M.; Gibb, E. A.; Gallina, A.; Raggi, D.; Marandino, L.; Bianchi, M.; Ross, J. S.; Colecchia, M.; Gandaglia, G.; Fossati, N.; Pederzoli, F.; Luciano, R.; Colombo, R.; Salonia, A.; Briganti, A.; Montorsi, F.; Necchi, A.
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study
2020-01-01 Necchi, Andrea; Raggi, Daniele; Giannatempo, Patrizia; Marandino, Laura; Farè, Elena; Gallina, Andrea; Colecchia, Maurizio; Lucianò, Roberta; Salonia, Andrea; Gandaglia, Giorgio; Fossati, Nicola; Bandini, Marco; Pederzoli, Filippo; Dittamore, Ryan; Liu, Yang; Davicioni, Elai; Ross, Jeffrey S; de Jong, Joep J; Briganti, Alberto; Montorsi, Francesco; Gibb, Ewan A
The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer
2020-01-01 Bandini, Marco; Calareso, Giuseppina; Raggi, Daniele; Marandino, Laura; Colecchia, Maurizio; Gallina, Andrea; Giannatempo, Patrizia; Pederzoli, Filippo; Gandaglia, Giorgio; Fossati, Nicola; Capitanio, Umberto; Colombo, Renzo; Salonia, Andrea; Briganti, Alberto; Montorsi, Francesco; De Cobelli, Francesco; Messina, Antonella; Necchi, Andrea
Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm?
2020-01-01 Pederzoli, Filippo; Bandini, Marco; Marandino, Laura; Raggi, Daniele; Giannatempo, Patrizia; Salonia, Andrea; Gallina, Andrea; Briganti, Alberto; Montorsi, Francesco; Necchi, Andrea
Targetable gene fusions and aberrations in genitourinary oncology
2020-01-01 Pederzoli, F.; Bandini, M.; Marandino, L.; Ali, S. M.; Madison, R.; Chung, J.; Ross, J. S.; Necchi, A.
The new era of precision urobiome: RE: “Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study” by Chipollini et al
2020-01-01 Alfano, M.; Pederzoli, F.; Bandini, M.; Necchi, A.
Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy
2020-01-01 Preisser, F.; Mazzone, E.; Knipper, S.; Nazzani, S.; Bandini, M.; Shariat, S. F.; Marchioni, M.; Tian, Z.; Saad, F.; Taussky, D.; Briganti, A.; Huland, H.; Graefen, M.; Tilki, D.; Karakiewicz, P. I.
Re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2020;77:55–65
2020-01-01 Montorsi, F.; Bandini, M.; Necchi, A.
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer
2020-01-01 Necchi, A.; Raggi, D.; Gallina, A.; Ross, J. S.; Fare, E.; Giannatempo, P.; Marandino, L.; Colecchia, M.; Luciano, R.; Bianchi, M.; Colombo, R.; Salonia, A.; Gandaglia, G.; Fossati, N.; Bandini, M.; Pederzoli, F.; Capitanio, U.; Montorsi, F.; de Jong, J. J.; Dittamore, R.; Liu, Y.; Davicioni, E.; Boormans, J. L.; Briganti, A.; Black, P. C.; Gibb, E. A.
Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab
2021-01-01 Necchi, A.; de Jong, J. J.; Raggi, D.; Briganti, A.; Marandino, L.; Gallina, A.; Bandini, M.; Dabbas, B.; Davicioni, E.; Capitanio, U.; Montorsi, F.; Seiler, R.; Wright, J. L.; Lotan, Y.; Black, P. C.; Gibb, E. A.
High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors?
2021-01-01 Fallara, G.; Bandini, M.; Larcher, A.; Pederzoli, F.; Karakiewicz, P.; Tian, Z.; Briganti, A.; Necchi, A.; Salonia, A.; Bertini, R.; Montorsi, F.; Bex, A.; Capitanio, U.
Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?
2021-01-01 Basile, G.; Pederzoli, F.; Bandini, M.; Raggi, D.; Gallina, A.; Salonia, A.; Briganti, A.; Montorsi, F.; Spiess, P. E.; Necchi, A.
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration
2021-01-01 Ravi, P.; Pond, G. R.; Diamantopoulos, L. N.; Su, C.; Alva, A.; Jain, R. K.; Skelton, W. P.; Gupta, S.; Tward, J. D.; Olson, K. M.; Singh, P.; Grunewald, C. M.; Niegisch, G.; Lee, J. -L.; Gallina, A.; Bandini, M.; Necchi, A.; Mossanen, M.; Mcgregor, B. A.; Curran, C.; Grivas, P.; Sonpavde, G. P.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC) | 1-gen-2020 | Foerster, B.; Abufaraj, M.; Mari, A.; Seisen, T.; Bandini, M.; Schweitzer, D.; Czech, A. K.; Moschini, M.; D'Andrea, D.; Bianchi, M.; Hendricksen, K.; Roupret, M.; Briganti, A.; van Rhijn, B. W. G.; Chlosta, P.; Colin, P.; John, H.; Shariat, S. F. | |
| Re: Siamak Daneshmand, Azadeh Nazemi. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. Eur Urol Focus 2020;6:639–41 | 1-gen-2020 | Basile, G.; Bandini, M.; Pederzoli, F.; Gallina, A.; Necchi, A. | |
| Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? | 1-gen-2020 | Necchi, A.; Marandino, L.; Raggi, D.; Bandini, M.; Gallina, A.; Moschini, M.; Briganti, A.; Montorsi, F. | |
| Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study | 1-gen-2020 | Bandini, M.; Pederzoli, F.; Madison, R.; Briganti, A.; Ross, J. S.; Niegisch, G.; Yu, E. Y.; Bamias, A.; Agarwal, N.; Sridhar, S. S.; Rosenberg, J. E.; Bellmunt, J.; Pal, S. K.; Galsky, M. D.; Luciano, R.; Gallina, A.; Salonia, A.; Montorsi, F.; Ali, S. M.; Chung, J. H.; Necchi, A. | |
| A risk calculator predicting recurrence in lymph node metastatic penile cancer | 1-gen-2020 | Bandini, M.; Spiess, P. E.; Pederzoli, F.; Marandino, L.; Brouwer, O. R.; Albersen, M.; Roussel, E.; de Vries, H. M.; Chipollini, J.; Zhu, Y.; Ye, D. -W.; Ornellas, A. A.; Catanzaro, M.; Hakenberg, O. W.; Heidenreich, A.; Haidl, F.; Watkin, N.; Ager, M.; Ahmed, M. E.; Karnes, J. R.; Briganti, A.; Salvioni, R.; Montorsi, F.; Azizi, M.; Necchi, A. | |
| Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma | 1-gen-2020 | Bandini, Marco; Ross, Jeffrey S; Zhu, Yao; Ye, Ding-Wei; Ornellas, Antonio A; Watkin, Nick; Ayres, Benjamin A; Hakenberg, Oliver W; Heidenreich, Axel; Salvioni, Roberto; Catanzaro, Mario; Raggi, Daniele; Giannatempo, Patrizia; Marandino, Laura; Haidl, Friederike; Pederzoli, Filippo; Briganti, Alberto; Montorsi, Francesco; Chipollini, Juan; Azizi, Mounsif; De Meerleer, Gert; Brouwer, Oscar R; Grass, G Daniel; Johnstone, Peter A; Albersen, Maarten; Spiess, Philippe E; Necchi, Andrea | |
| Reply to Yunjin Bai, Yubo Yang, Yin Tang's Letter to the Editor, re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01, Study. Eur Urol 2020;77:636–43 | 1-gen-2020 | Bandini, M.; Necchi, A. | |
| Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆ | 1-gen-2020 | Bandini, M.; Gibb, E. A.; Gallina, A.; Raggi, D.; Marandino, L.; Bianchi, M.; Ross, J. S.; Colecchia, M.; Gandaglia, G.; Fossati, N.; Pederzoli, F.; Luciano, R.; Colombo, R.; Salonia, A.; Briganti, A.; Montorsi, F.; Necchi, A. | |
| Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study | 1-gen-2020 | Necchi, Andrea; Raggi, Daniele; Giannatempo, Patrizia; Marandino, Laura; Farè, Elena; Gallina, Andrea; Colecchia, Maurizio; Lucianò, Roberta; Salonia, Andrea; Gandaglia, Giorgio; Fossati, Nicola; Bandini, Marco; Pederzoli, Filippo; Dittamore, Ryan; Liu, Yang; Davicioni, Elai; Ross, Jeffrey S; de Jong, Joep J; Briganti, Alberto; Montorsi, Francesco; Gibb, Ewan A | |
| The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer | 1-gen-2020 | Bandini, Marco; Calareso, Giuseppina; Raggi, Daniele; Marandino, Laura; Colecchia, Maurizio; Gallina, Andrea; Giannatempo, Patrizia; Pederzoli, Filippo; Gandaglia, Giorgio; Fossati, Nicola; Capitanio, Umberto; Colombo, Renzo; Salonia, Andrea; Briganti, Alberto; Montorsi, Francesco; De Cobelli, Francesco; Messina, Antonella; Necchi, Andrea | |
| Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm? | 1-gen-2020 | Pederzoli, Filippo; Bandini, Marco; Marandino, Laura; Raggi, Daniele; Giannatempo, Patrizia; Salonia, Andrea; Gallina, Andrea; Briganti, Alberto; Montorsi, Francesco; Necchi, Andrea | |
| Targetable gene fusions and aberrations in genitourinary oncology | 1-gen-2020 | Pederzoli, F.; Bandini, M.; Marandino, L.; Ali, S. M.; Madison, R.; Chung, J.; Ross, J. S.; Necchi, A. | |
| The new era of precision urobiome: RE: “Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study” by Chipollini et al | 1-gen-2020 | Alfano, M.; Pederzoli, F.; Bandini, M.; Necchi, A. | |
| Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy | 1-gen-2020 | Preisser, F.; Mazzone, E.; Knipper, S.; Nazzani, S.; Bandini, M.; Shariat, S. F.; Marchioni, M.; Tian, Z.; Saad, F.; Taussky, D.; Briganti, A.; Huland, H.; Graefen, M.; Tilki, D.; Karakiewicz, P. I. | |
| Re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2020;77:55–65 | 1-gen-2020 | Montorsi, F.; Bandini, M.; Necchi, A. | |
| Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer | 1-gen-2020 | Necchi, A.; Raggi, D.; Gallina, A.; Ross, J. S.; Fare, E.; Giannatempo, P.; Marandino, L.; Colecchia, M.; Luciano, R.; Bianchi, M.; Colombo, R.; Salonia, A.; Gandaglia, G.; Fossati, N.; Bandini, M.; Pederzoli, F.; Capitanio, U.; Montorsi, F.; de Jong, J. J.; Dittamore, R.; Liu, Y.; Davicioni, E.; Boormans, J. L.; Briganti, A.; Black, P. C.; Gibb, E. A. | |
| Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab | 1-gen-2021 | Necchi, A.; de Jong, J. J.; Raggi, D.; Briganti, A.; Marandino, L.; Gallina, A.; Bandini, M.; Dabbas, B.; Davicioni, E.; Capitanio, U.; Montorsi, F.; Seiler, R.; Wright, J. L.; Lotan, Y.; Black, P. C.; Gibb, E. A. | |
| High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors? | 1-gen-2021 | Fallara, G.; Bandini, M.; Larcher, A.; Pederzoli, F.; Karakiewicz, P.; Tian, Z.; Briganti, A.; Necchi, A.; Salonia, A.; Bertini, R.; Montorsi, F.; Bex, A.; Capitanio, U. | |
| Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand? | 1-gen-2021 | Basile, G.; Pederzoli, F.; Bandini, M.; Raggi, D.; Gallina, A.; Salonia, A.; Briganti, A.; Montorsi, F.; Spiess, P. E.; Necchi, A. | |
| Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration | 1-gen-2021 | Ravi, P.; Pond, G. R.; Diamantopoulos, L. N.; Su, C.; Alva, A.; Jain, R. K.; Skelton, W. P.; Gupta, S.; Tward, J. D.; Olson, K. M.; Singh, P.; Grunewald, C. M.; Niegisch, G.; Lee, J. -L.; Gallina, A.; Bandini, M.; Necchi, A.; Mossanen, M.; Mcgregor, B. A.; Curran, C.; Grivas, P.; Sonpavde, G. P. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile